Luke Evnin Sells 39,560 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 39,560 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $0.93, for a total transaction of $36,790.80. Following the completion of the transaction, the director directly owned 3,552,501 shares in the company, valued at $3,303,825.93. This represents a 1.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total value of $34,789.95.
• On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $57,204.56.
• On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.09, for a total value of $28,450.09.
• On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.14, for a total value of $40,832.52.
• On Monday, November 10th, Luke Evnin sold 31,172 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total value of $36,782.96.
• On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.11, for a total value of $48,784.50.
• On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $42,285.87.
• On Wednesday, November 5th, Luke Evnin sold 30,774 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $37,544.28.
• On Tuesday, November 4th, Luke Evnin sold 90,164 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.22, for a total transaction of $110,000.08.
• On Monday, November 3rd, Luke Evnin sold 60,369 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.29, for a total transaction of $77,876.01.

Werewolf Therapeutics Trading Down 0.5%

Werewolf Therapeutics stock opened at $0.92 on Wednesday. Werewolf Therapeutics, Inc. has a 52-week low of $0.60 and a 52-week high of $2.38. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $44.42 million, a price-to-earnings ratio of -0.56 and a beta of 0.72. The firm has a 50-day moving average price of $1.56 and a two-hundred day moving average price of $1.34.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. Sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.

Analysts Set New Price Targets

HOWL has been the subject of several recent analyst reports. JMP Securities decreased their price target on Werewolf Therapeutics from $4.00 to $3.00 and set a “market outperform” rating for the company in a research note on Thursday, August 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, October 8th. Citigroup reissued a “market outperform” rating on shares of Werewolf Therapeutics in a research note on Wednesday, November 12th. Bank of America reduced their price target on shares of Werewolf Therapeutics from $8.00 to $7.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Zacks Research upgraded shares of Werewolf Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 16th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Werewolf Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $7.75.

Hedge Funds Weigh In On Werewolf Therapeutics

Large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. grew its stake in shares of Werewolf Therapeutics by 33.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,712 shares of the company’s stock worth $93,000 after purchasing an additional 23,852 shares during the last quarter. MPM Asset Management LLC lifted its stake in Werewolf Therapeutics by 0.6% during the first quarter. MPM Asset Management LLC now owns 4,309,860 shares of the company’s stock valued at $4,189,000 after purchasing an additional 25,688 shares during the last quarter. MPM Bioimpact LLC boosted its holdings in Werewolf Therapeutics by 0.9% during the first quarter. MPM Bioimpact LLC now owns 2,408,810 shares of the company’s stock worth $2,341,000 after buying an additional 20,799 shares in the last quarter. Nuveen LLC acquired a new position in Werewolf Therapeutics in the first quarter worth approximately $71,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter valued at $92,000. Institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.